Eli Lilly's oral weight loss drug sees over 5,600 prescriptions in third week
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,110.73 +0.78%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: +39.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: +39.6%
Join SI Premium – FREE
Investing.com -- Eli Lilly's newly launched oral weight loss drug received 5,612 prescriptions in the United States during its third week on the market, according to analysts citing IQVIA data.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly plans European weight-loss pill launch by early 2027
- Israel said to eye US listing for major defense firms
- Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%
Create E-mail Alert Related Categories
InvestingRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
